CN1775267A - A kind of open arrow extract and its preparation method and application - Google Patents
A kind of open arrow extract and its preparation method and application Download PDFInfo
- Publication number
- CN1775267A CN1775267A CNA2005101008321A CN200510100832A CN1775267A CN 1775267 A CN1775267 A CN 1775267A CN A2005101008321 A CNA2005101008321 A CN A2005101008321A CN 200510100832 A CN200510100832 A CN 200510100832A CN 1775267 A CN1775267 A CN 1775267A
- Authority
- CN
- China
- Prior art keywords
- extract
- tupistra chinensis
- chinensis bak
- tupistra
- bak
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 241001621801 Rohdea chinensis Species 0.000 claims abstract description 127
- 239000003814 drug Substances 0.000 claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 35
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 35
- 229930182490 saponin Natural products 0.000 claims description 35
- 150000007949 saponins Chemical class 0.000 claims description 35
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 22
- 239000000287 crude extract Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000000605 extraction Methods 0.000 claims description 16
- 239000011347 resin Substances 0.000 claims description 15
- 229920005989 resin Polymers 0.000 claims description 15
- 239000003146 anticoagulant agent Substances 0.000 claims description 11
- 230000000259 anti-tumor effect Effects 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 10
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 229940127219 anticoagulant drug Drugs 0.000 claims description 7
- 241000234280 Liliaceae Species 0.000 claims description 6
- 241001448528 Tupistra Species 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 125000002345 steroid group Chemical group 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 14
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 238000012360 testing method Methods 0.000 abstract description 7
- 239000006260 foam Substances 0.000 abstract description 5
- 230000004520 agglutination Effects 0.000 abstract description 3
- 239000000843 powder Substances 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract description 2
- -1 steroid saponin compound Chemical class 0.000 abstract description 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- IUCHKMAZAWJNBJ-RCYXVVTDSA-N oleanolic acid 3-O-beta-D-glucosiduronic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O IUCHKMAZAWJNBJ-RCYXVVTDSA-N 0.000 description 7
- 241001529246 Platymiscium Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000008055 phosphate buffer solution Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 230000000702 anti-platelet effect Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- FLDVFDQHJBXYFP-UHFFFAOYSA-N convallagenin B Natural products CC1C(C2(CCC3C4(C)C(O)CC(O)C(O)C4(O)CCC3C2C2)C)C2OC11CCC(C)CO1 FLDVFDQHJBXYFP-UHFFFAOYSA-N 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FLDVFDQHJBXYFP-PBVSVCIJSA-N Convallagenin B Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)[C@H](O)C[C@H](O)[C@H](O)[C@@]4(O)CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 FLDVFDQHJBXYFP-PBVSVCIJSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- QMQIQBOGXYYATH-IDABPMKMSA-N Ruscogenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)[C@H](O)C[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 QMQIQBOGXYYATH-IDABPMKMSA-N 0.000 description 2
- BSUPFYRQXCQGLJ-UHFFFAOYSA-N Ruscogenin Natural products CC1CCC2(OC1)OC3C(O)C4C5CC=C6CC(O)CC(O)C6(C)C5CCC4(C)C3C2C BSUPFYRQXCQGLJ-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- QMQIQBOGXYYATH-UHFFFAOYSA-N epiruscogenin Natural products CC1C(C2(CCC3C4(C)C(O)CC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 QMQIQBOGXYYATH-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 229940109990 ruscogenin Drugs 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 229930184979 wattoside Natural products 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LPBMOSUWZHYSFA-UHFFFAOYSA-N 1beta,2beta,3beta,4beta,5beta-pentahydroxyspirost-25(27)-ene Natural products CC1C(C2(CCC3C4(C)C(O)C(O)C(O)C(O)C4(O)CCC3C2C2)C)C2OC11CCC(=C)CO1 LPBMOSUWZHYSFA-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 241000827798 Hemerocallis citrina Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- HFMLTKBZNAPPNY-UHFFFAOYSA-N Rhodexin A Natural products OC1C(O)C(O)C(C)OC1OC1CC(CCC2C3(CCC(C3(C)CC(O)C32)C=2COC(=O)C=2)O)C3(C)CC1 HFMLTKBZNAPPNY-UHFFFAOYSA-N 0.000 description 1
- 241001181347 Rohdea aurantiaca Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940085393 aspirin 150 mg Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 201000011061 large intestine cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- LLALJIDXOPBDFG-UHFFFAOYSA-N ranmodenin A Natural products CC1C(C2(CCC3C4(C)C(O)CC(O)C(O)C4(O)CCC3C2C2)C)C2OC11CCC(=C)CO1 LLALJIDXOPBDFG-UHFFFAOYSA-N 0.000 description 1
- LLALJIDXOPBDFG-NPTSYTKOSA-N ranmogenin a Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)[C@H](O)C[C@H](O)[C@H](O)[C@@]4(O)CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CCC(=C)CO1 LLALJIDXOPBDFG-NPTSYTKOSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- NSPSSDCJLOQASC-FXRXPBCOSA-N rhodexin A Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@H](CC[C@H]2[C@]3(CC[C@@H]([C@@]3(C)C[C@@H](O)[C@H]32)C=2CCC(=O)C=2)O)[C@]3(C)CC1 NSPSSDCJLOQASC-FXRXPBCOSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- LPBMOSUWZHYSFA-KLOHSWDASA-N δ-25(27)-pentrogenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@]4(O)CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CCC(=C)CO1 LPBMOSUWZHYSFA-KLOHSWDASA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a Chinese medicine tupistra chinensis extract, its preparation method and application. Said extract is obtained by extracting root, stem and leaf of tupistra chinensis, and is a brownish yellow powder. The characteristics of its chemical identification are as follows: Liebermann-Burchard reaction and Molish reaction are positive; the foam test is positive reaction, the foam height of alkaline liquor tube is higher than that of acid liquor tube; Rosen-Heimer reaction at 60deg.C can produce violet red color reaction, it is a steroid saponin compound. Said extract has the action of resisting tumor, resisting inflammation, inhibiting platelet agglutination and resisting thrombosis.
Description
Invention field
The present invention relates to the field of Chinese medicines, particularly a kind of Chinese medicine extract and its production and application is specifically related to Tupistra chinensis Bak. extract and its production and application.
Background technology
Tupistra chinensis Bak. belongs to (Tupistra) plant and is under the jurisdiction of Liliaceae (Liliaceae) Herba Convallariae family (Convallarieae).The Tupistra chinensis Bak. platymiscium has kind more than 20, and China is world's Tupistra chinensis Bak. platymiscium center of distribution, and kind accounts for 70% of the whole world.Tupistra chinensis Bak. is that the very high plant of Chinese endemic element belongs to, and mainly is distributed in southern areas such as China Sichuan, Hubei, Yunnan, Zhejiang, Guangxi, Jiangxi, Fujian.
The Tupistra chinensis Bak. platymiscium is China's medication among the people, how to be used as medicine with rhizome and Herb.Traditional Chinese medical science traditional theory is thought this platymiscium hardship, suffering, and is cold in nature, poisonous, has effects such as heat-clearing and toxic substances removing, expelling wind and removing dampness, eliminating stasis to stop pain, cures mainly diphtheria, laryngopharynx swelling and pain, rheumatic arthralgia, traumatic injury, stomachache, carbuncle sore tumefacting virus, poisonous snake lyssodexis etc.
The Tupistra chinensis Bak. platymiscium of existing at present research report has Tupistra chinensis Bak. (Tupistra chinensis Baker), curved stamen Tupistra chinensis Bak. (Tupistra wattii Hook.f.), tooth lobe Tupistra chinensis Bak. (Tupistra fimbriata Hand.-Mazz.) and Hemerocallis citrina Baroni Tupistra chinensis Bak. kinds more than 10 such as (Tupistra aurantiaca Wall.).Studies show that the contained chemical constituent of Tupistra chinensis Bak. platymiscium mostly is steroidal compounds, all contain steroid saponin (" Chinese wild plant resource ", 1999,19 (5): 59-62).Shen equality has been carried out separation, purification to the ethanol extraction of curved stamen Tupistra chinensis Bak., and measures the cytotoxic activity of the chemical compound that obtains with tumor cell K562 that cultivates and A2780a.Found that curved stamen ruscogenin B (wattigenin B), curved stamen ruscogenin C (Wattigenin C), steroid sapogenines (kitigenin) and convallagenin B (convallagenin B), and cardiotonic glycoside rhodexin A, wattoside F, wattoside E etc. have cytotoxic activity (" time precious traditional Chinese medical science traditional Chinese medicines " 2005,15 (12): 860-861).Taiwan's scholars Pan Wen refined (Pan WB) etc. produce Tupistra chinensis Bak. to the continent and have carried out similar research, find that steroid sapogenines Δ 25 (27)-pentrogenin, ranmogenin A etc. have cytotoxic activity (J.Nat.Prod. to the gastric carcinoma cells of cultivating (NUGC), 2003,66 (2): 161-168).Yet the antitumor action of the chemical compound of these Tupistra chinensis Bak. platymisciums is the result that the cell in vitro cytotoxic activity is measured, and the result who whether has antitumor action still not have experimentation at present in the body is confirmed.It once is principal agent with the Tupistra chinensis Bak. that old state just waits, and forms prescription QE-8407, has carried out anticancer pharmacology and clinical trial, and confirming has inhibitory action (" Yunnan University's journal " (natural science edition), 1989,1: 55) to tumor strains such as W256.But whether independent use has antitumor action for Tupistra chinensis Bak., and what chemical compound has problems such as antitumor action not do further research.In addition, there are some researches show also that Tupistra chinensis Bak. eliminates the phlegm, antiinflammatory and antibacterial (" folks of china medical magazine ", 2005,2:103-106), and effect (" Changjiang University's journal " (natural science edition), 2005,2 (2): 77-82) such as antifungal.These researchs are object with the methanol crude extract of Tupistra chinensis Bak. all, do not determine the compound property of Tupistra chinensis Bak. active component.
Summary of the invention
The object of the invention is to provide a kind of Tupistra chinensis Bak. extract.
Another purpose of the present invention provides a kind of Tupistra chinensis Bak. preparation method of extract.
Another purpose of the present invention provides a kind of pharmaceutical composition that contains the Tupistra chinensis Bak. extract.
Another purpose of the present invention provides the application of Tupistra chinensis Bak. extract in preparation treatment antitumor, antiinflammatory and anticoagulant medicine.
Tupistra chinensis Bak. extract of the present invention is that (Tupistra chinenese, Baker) extraction obtains from Liliaceae (Liliaceae) Tupistra chinensis Bak. genus (Tupistra) plant Tupistra chinensis Bak..
Tupistra chinensis Bak. of the present invention can be its rhizome, leaf or herb.
Tupistra chinensis Bak. extract of the present invention is a steroid oside compound, is pale brown toner powder.Being characterized as of its chemical identification: Liebermann-Burchard reaction, Molish reaction all are positive; Foam stability test is positive, and the foam height of alkali liquor pipe is than the foam height of acid solution pipe; Rosen-Heimer presents the aubergine chromogenic reaction when being reflected at 60 ℃.
Tupistra chinensis Bak. method for preparing extractive of the present invention can adopt oside compound separating and extracting process commonly used.
Tupistra chinensis Bak. method for preparing extractive of the present invention contains following steps: a prepares crude extract; The b purification.
Tupistra chinensis Bak. method for preparing extractive step a of the present invention can use Chinese medicine crude extract preparation method commonly used.For example the Tupistra chinensis Bak. water can be decocted, or obtain containing the Tupistra chinensis Bak. crude extract of Saponin with the 1-4 carbon alcoholic solution reflux Tupistra chinensis Bak. of variable concentrations.1-4 carbon alcohol of the present invention can be methanol, ethanol, propanol, isopropyl alcohol, n-butyl alcohol wherein one or more, preferably methanol and ethanol are wherein a kind of.
In the Tupistra chinensis Bak. method for preparing extractive of the present invention, Tupistra chinensis Bak. can use its rhizome, leaf or herb.
The Saponin purification process that Tupistra chinensis Bak. method for preparing extractive step b of the present invention can adopt those skilled in the art to use always.
Tupistra chinensis Bak. method for preparing extractive of the present invention, purification process can adopt extraction: the Tupistra chinensis Bak. crude extract is concentrated the extractum that obtains be dissolved in the water, extract with 4 or 5 carbon alcohol; Extract reclaims the Tupistra chinensis Bak. extract that the solvent after drying obtains containing total Saponin.Of the present invention 4 or 5 carbon alcohol can be n-butyl alcohol, isobutanol, n-amyl alcohol wherein one or more, n-butyl alcohol preferably.
In above-mentioned abstraction purification method, Tupistra chinensis Bak. crude extract extractum aqueous solution can be used organic solvent degreasing earlier.Described organic solvent can be chloroform, ethyl acetate, ether, petroleum ether wherein one or more.
In above-mentioned abstraction purification method, obtaining extract can precipitate with acetone or ether etc., reclaims precipitate, obtains the higher total Saponin of purity with this.
Tupistra chinensis Bak. method for preparing extractive of the present invention, purification process can also adopt chromatography.Chromatography of the present invention can be that macroporous resin chromatography, silica gel chromatography, alumina column chromatography method are wherein a kind of.Chromatography of the present invention is the macroporous resin chromatography preferably
Macroporous resin chromatography concrete steps of the present invention are: on the Tupistra chinensis Bak. crude extract behind the macroporous resin chromatographic column, after elder generation's water is eluted to the no polysaccharide chromogenic reaction of phenolsulfuric acid method mensuration, carry out eluting with ethanol then, collect the male position of Saponin chromogenic reaction, concentrate drying obtains the Tupistra chinensis Bak. extract.
Macroporous resin of the present invention is nonpolar or low pole polystyrene macroporous resin, for example HPD-100, D-101, AB-8, HP-20, HPD-300 etc.Macroporous resin of the present invention is the HPD-100 macroporous resin preferably.
The pharmaceutical composition that contains the Tupistra chinensis Bak. extract of the present invention contains the Tupistra chinensis Bak. extract and the adjuvant or the excipient commonly used for the treatment of effective dose.Can obtain the Tupistra chinensis Bak. extract according to method known to those skilled in the art and preferably use consumption and form.Those skilled in the art can obtain the type of service and the consumption of used adjuvant, excipient according to methods known in the art.
The pharmaceutical composition that contains the Tupistra chinensis Bak. extract of the present invention adopts this area preparation method commonly used.For example promptly with above-mentioned Tupistra chinensis Bak. extract and pharmaceutical adjuvant mix homogeneously.
The pharmaceutical composition that contains the Tupistra chinensis Bak. extract of the present invention, its dosage form can be any in injection, tablet, pill, capsule, electuary, oral liquid, suspension, spray, externally-applied liniment, the cutaneous permeable agent.Those skilled in the art can obtain used dosage form according to methods known in the art.
Tupistra chinensis Bak. extract of the present invention has antitumor action, antiinflammatory action and anticoagulant, anti thrombotic action.For a better understanding of the present invention, with relevant pharmacological testing of the present invention and result its purposes is described below.
One, antitumor action
1. the activity of the external tumor of the total Saponin of Tupistra chinensis Bak.
The total Saponin I of Tupistra chinensis Bak. of embodiment 1 preparation is mixed with 2mg/mL solution with phosphate buffer solution (PBS), and after the filtration sterilization, the aseptic PBS of reuse is diluted to 20 μ g/mL, 40 μ g/mL, 80 μ g/ μ L, 160 μ g/mL, 320 μ g/mL.
K562: human leukemia cell; HepG2: human liver cancer cell; LoVo: human large intestine cancer cell; C6: rat neuroglial cytoma; MCF7: human breast cancer cell; All cultivate, by 2.0 * 10 with the DMEM that adds 10% new-born calf serum
3Individual/hole is inoculated in 96 orifice plates, volume 90 μ L.Cultivate after 48 hours, every hole adds the extract 10 μ L of variable concentrations, and promptly final concentration is respectively 2 μ g/mL, 4 μ g/mL, 8 μ g/mL, 16 μ g/mL, 32 μ g/mL.Blank is PBS, and matched group and medicine group are all established 6 parallel holes.Continue to cultivate 48 hours, the adding volume ratio is 1: 10 a CCK-8 reagent, hatches 2.5 hours, measures 450nm absorbance (OD value) on the microplate reader, and reference wavelength is 630nm.Be calculated as follows suppression ratio: suppression ratio (%)=[1-(the average OD value of the medication group/average OD value of blank group)] * 100%, and according to the half-inhibition concentration (IC of the total Saponin of suppression ratio calculating Tupistra chinensis Bak. to various tumors
50), the results are shown in Table 1.
The total Saponin I of table 1. Tupistra chinensis Bak. is to the tumor cell proliferation inhibition effect
| Concentration (μ g/mL) | Suppression ratio (%) | ||||
| K562 | LoVo | HepG2 | C6 | MCF7 | |
| 2 4 8 16 32 | 27.4 47.9 61.2 71.9 82.2 | 28.6 50.9 63.0 71.7 84.9 | 41.4 51.8 66.5 81.6 92.3 | 20.1 38.1 56.3 61.4 79.0 | 44.8 57.9 73.6 87.9 93.2 |
| IC 50(μg/mL) | 5.22 | 4.72 | 3.37 | 7.68 | 2.65 |
Total Saponin III and separated part B, the C of the total Saponin II of Tupistra chinensis Bak. of embodiment 2 preparation and embodiment 3 preparations, (position A separates because of indissoluble D, and content is few, do not carry out this test) be mixed with 2mg/mL solution with phosphate buffer solution, after the filtration sterilization, the aseptic PBS of reuse is diluted to 20 μ g/mL, 40 μ g/mL, 80 μ g/mL, 160 μ g/mL.The same method is measured the activity that each sample suppresses the HepG2 cell proliferation.The results are shown in Table 2.The result shows that the total Saponin of Tupistra chinensis Bak. and each separated part thereof all have inhibitory action to the HepG2 tumor cell proliferation, and strong with acting as of polarity position B on the low side.
Total Saponin of table 2. Tupistra chinensis Bak. and separated part are to the effect of HepG2 tumor cell proliferation inhibition
| Concentration (μ g/mL) | Total Saponin II | Total Saponin III | Position B | Position C | Position D |
| 2 4 8 16 | 21.2 42.9 62.7 88.9 | 17.4 38.6 52.3 79.8 | 52.9 78.8 96.5 98.2 | 8.5 26.7 41.7 66.9 | 2.3 10.1 23.4 42.1 |
| IC 50(μg/mL) | 4.87 | 6.27 | ＜2.0 | 9.55 | 19.24 |
2, the activity of the total Saponin in-vivo tumour of Tupistra chinensis Bak.
The total Saponin I of the Tupistra chinensis Bak. physiological saline solution of embodiment 1 preparation is mixed with the solution of 0.1g/mL and 0.2g/mL, filtration sterilization, and-20 ℃ of preservations are faced with before thawing after the packing.
With the S that inoculates 7 days
180Ascites of sarcoma mice and normal saline dilute in 1: 1 ratio, the right groin subcutaneous injection of mice 0.2mL diluent, and press the body weight random packet: 11 of normal saline matched groups, two groups number of animals is 10 in addition.
The calculating of medication and tumour inhibiting rate: beginning administration in the 2nd day after the mouse inoculation tumor, once a day, continuous 8 days.Dosage is respectively: ring phosphamide (CTX) group 20mg/kg lumbar injection, and the total Saponin of Tupistra chinensis Bak. is pressed 0.2mL/10g body weight gastric infusion, and dosage is respectively 2.0g/kg and 4.0g/kg.Put to death mice, and peeled off the tumor piece and weigh in the 2nd day after the last administration.Calculate tumour inhibiting rate by " tumour inhibiting rate=(1-administration group tumor weight/normal saline matched group tumor is heavy) * 100% " formula.Experimental result sees Table 3.
The total Saponin of table 3. Tupistra chinensis Bak. is to the inhibitory action of S180 tumor-bearing mice tumor growth
| Grouping | Number of animals | Tumor heavy (g) | Suppression ratio |
| Normal saline contrast CTX (20mg/kg) Tupistra chinensis Bak. (2.0g/kg) Tupistra chinensis Bak. (4.0g/kg) | 11 10 10 10 | 2.14±0.61 0.81±0.41** 1.19±0.53** 1.02±0.58** | 62.1％ 44.4％ 52.3％ |
Annotate: compare * * p＜0.01 with the normal saline matched group.
Two, antiinflammatory action
The total Saponin III of the Tupistra chinensis Bak. physiological saline solution of embodiment 3 preparation is mixed with the solution of 0.1g/mL and 0.2g/mL, filtration sterilization, and-20 ℃ of preservations are faced with before thawing after the packing.
Bring out the antiinflammatory action of the total Saponin of inflammatory model check Tupistra chinensis Bak. of mice auricle swelling with dimethylbenzene: 48 of mices, male and female half and half are divided into 4 groups at random.Positive controls lumbar injection aspirin 150mg/kg, the total Saponin III of Tupistra chinensis Bak. is with 0.2ml/10g body weight gastric infusion, and negative control group is given with the volume normal saline and is irritated stomach.Every day 1 time, continuous 7 days.After the last administration 2 hours, each group mouse right ear upper and lower faces is smeared dimethylbenzene 20 μ l respectively, left ear is not coated with in contrast, puts to death mice after 1 hour, cuts ears, sweeps away auricle with the card punch of 8mm diameter, and balance is weighed.Deduct left ear weight as the swelling degree with auris dextra weight, calculate inhibitory rate of intumesce as follows: inhibitory rate of intumesce=(negative control group difference-administration group difference)/negative control group difference * 100%.The results are shown in Table 4.The result shows that the total Saponin of Tupistra chinensis Bak. can suppress the mice caused by dimethylbenzene xylene auricle edema, has significant antiinflammatory action.
The total Saponin III of table 4. Tupistra chinensis Bak. xylol causes the influence of mice auricle swelling
| Group | Number of animals | Swelling degree (mg) | Suppression ratio |
| Normal saline aspirin (150mg/kg) Tupistra chinensis Bak. (2.0g/kg) | 12 12 12 | 13.13±4.18 8.17±2.54** 10.14±3.61 | 37.8％ 22.8％ |
| Tupistra chinensis Bak. (4.0g/kg) | 12 | 9.10±3.04* | 30.7％ |
Annotate: compare * p＜0.05, * * p＜0.01 with the normal saline matched group.
Three, antiplatelet aggregative activity
The total Saponin I of the Tupistra chinensis Bak. physiological saline solution of embodiment 1 preparation is mixed with the solution of 5mg/mL, 10mg/mL, 20mg/mL, 40mg/mL.
External anti-platelet aggregation effect: the rabbit auricular vein is got blood, the anticoagulant in 1: 9 of 3.8% sodium citrate.900 rev/mins centrifugal 8 minutes, getting the upper strata, to be rich in platelet blood plasma standby.The blood plasma of drawing PRP is continued centrifugal, 3000 rev/mins centrifugal 20 minutes, get platelet poor plasma.Use the turbidimetry for Determination platelet aggregation rate.Get and be rich in platelet blood plasma 0.27mL and add in the test cup, add the total Saponin I of 30 μ L Tupistra chinensis Bak., matched group is with 10 μ L physiologic saline for substitute, 37 ℃ hatch 2 minutes after, add the gathering of Adenosine diphosphate (ADP) induced platelet.
The result shows that the total Saponin of Tupistra chinensis Bak. has tangible antiplatelet aggregative activity, and is dose-effect relationship.Calculate platelet aggregation inhibition rate with the platelet maximum agglutination rate, calculate as follows: suppression ratio=(matched group aggregation rate-administration group aggregation rate)/matched group aggregation rate * 100%.The results are shown in Table 5.The IC of the total Saponin anticoagulant of Tupistra chinensis Bak.
50Be 3.18mg/mL.
The total Saponin I of table 5. Tupistra chinensis Bak. antiplatelet aggregative activity
| Group | Number of times (n) | Maximum agglutination rate | Suppression ratio |
| Normal saline Tupistra chinensis Bak. (0.5mg/mL) Tupistra chinensis Bak. (1.5mg/mL) Tupistra chinensis Bak. (2.0mg/mL) | 5 5 5 5 | 41.79±7.26 36.45±7.36 31.52±5.83* 24.35±5.21** | 12.8％ 24.6％ 41.7％ |
| Tupistra chinensis Bak. (4.0mg/mL) | 5 | 11.87±4.42** | 53.6％ |
Annotate: compare * p＜0.05, * * p＜0.01 with the normal saline matched group.
Major advantage of the present invention has:
1. the total Saponin of Tupistra chinensis Bak. provided by the invention has effects such as definite antitumor, antiinflammatory and anticoagulant, and value for clinical application is preferably arranged.
2. the preparation of the total Saponin of Tupistra chinensis Bak. of the present invention can be adopted methods such as extraction and resin chromatography, and easy to operation, the reaction condition gentleness is suitable for and applies.
3. Tupistra chinensis Bak. raw medicinal material of the present invention is comparatively common in province, China south, and the medicine source is wider, is easy to realize industrialization.
The specific embodiment
Following examples make those skilled in the art more fully understand the present invention, but do not limit the present invention in any way.
Embodiment 1
Tupistra chinensis Bak. rhizome thin slice (2～4mm) 0.2 kilograms, add 1.5 premium on currency, to soak after 6 hours, heating decocted 2 hours, and the water outlet decocting liquid inclines; Add 1.5 liters in water then, continue to decoct 1.5 hours, the water outlet decocting liquid that inclines adds 1.5 liters in water again, decocts 1.5 hours with quadrat method; Merge 3 times decocting liquid, filter, standby.
The HPD-100 macroporous resin column chromatography: HPD-100 macroporous resin bed volume is 4.5cm (internal diameter) * 58cm (height), about 920mL.Sample on the above-mentioned Tupistra chinensis Bak. decocting liquid is used the distilled water eluting, about 1.8 liters/hour of flow velocity.Behind about 5 liters of distilled water flushings, effluent detects the polysaccharide reaction with sulfuric acid-phynol method and is light yellow; Then with 2.5 liters of eluting of 20% ethanol, 3 liter of 70% ethanol elution of reuse.Collect the position of 70% ethanol elution, detection Liebermann-Burchard reaction, Molish reaction all are positive, and are illustrated as Saponin class material.The position heat drying of 70% ethanol elution obtains total Saponin I, about 20.1 grams of weighing, and yield is 10.0%.
Contain drug regimen composition formula of Tupistra chinensis Bak. extract and preparation method thereof:
Tablet: 1000 amounts (200mg/ sheet)
(1) prescription:
Above-mentioned Tupistra chinensis Bak. extract 200g
Starch 40g
Dextrin 40g
Stearic acid 6.4g
(2) preparation method:
According to above-mentioned prescription mixing → every heavily about 300mg of an amount of alcohol granulation → 60-80 ℃ oven dry → tabletting sieves → add.
Embodiment 2
(2～4mm) 0.2 kilograms of Tupistra chinensis Bak. rhizome thin slices, use 1.5 liters 95% ethanol, 75% ethanol and 50% ethanol respectively successively, heating and refluxing extraction 2 hours, merge extractive liquid,, ethanol is reclaimed in distilling under reduced pressure, and resulting extractum adds the dissolving of 400 ml distilled waters, place in the separatory funnel, add 200 milliliters of petroleum ether extractiones 3 times, vibrated 5 minutes at every turn, left standstill 0.5 hour; Lower aqueous solution vibrated 5 minutes with the saturated n-butanol extraction of 200 ml waters 4 times at every turn, left standstill 1 hour.Merge n-butanol extraction solution, n-butyl alcohol is reclaimed in distilling under reduced pressure, and residue dissolves with 50 ml methanol, add 500 milliliters of acetone, standing over night, carefully inclining upper solution, precipitate Liebermann-Burchard reaction after testing, Molish reaction all are positive, and are Saponin class material.60 ℃ of vacuum dryings of precipitate obtain total Saponin II, 22.8 grams of weighing, and yield is 11.4%.
Contain drug regimen composition formula of Tupistra chinensis Bak. extract and preparation method thereof: 1000 bottles of amounts of freeze-dried powder (injection) (100mg/ props up)
(1) prescription:
Above-mentioned Tupistra chinensis Bak. extract 100g
Active carbon 25g
Water for injection is to 5000ml
(2) preparation method:
With water for injection the dissolving of total Saponin is added active carbon → mixing → be heated to 80 ℃ * 30min → buchner funnel to filter → 0.2 μ m membrane filtration degerming → packing, every bottle of 5ml → partly cover plug → lyophilization → gland.
Embodiment 3
(2～4mm) 0.2 kilograms of Tupistra chinensis Bak. rhizome thin slices, add 1.5 liters of methanol, heating and refluxing extraction 2 hours is extracted merge extractive liquid, repeatedly 4 times, methanol is reclaimed in distilling under reduced pressure, resulting extractum adds the dissolving of 400 ml distilled waters, places in the separatory funnel, adds 200 milliliters of petroleum ether extractiones 3 times, each vibration 5 minutes was left standstill 0.5 hour; Lower aqueous solution vibrated 5 minutes with the saturated n-butanol extraction of 200 ml waters 4 times at every turn, left standstill 1 hour.Merge n-butanol extraction solution, n-butyl alcohol is reclaimed in distilling under reduced pressure, and residue Liebermann-Burchard reaction after testing, Molish reaction all are positive, and for Saponin class material, promptly obtain total Saponin, and 25.4g weighs.Get the total Saponin dissolve with methanol of 12g, stir with H type tlc silica gel, air-dry standby.
Get the above-mentioned silica gel of mixing sample, place the dried post of H type tlc silica gel (2.6 * 73cm) tops, highly about 5.3cm.Analyse eluting with the water saturation n-butanol layer, thin layer chromatography result according to effluent, collected A, B, four positions of C, D by effusive order (polarity grows from weak to strong), the Liebermann-Burchard at four positions reaction after testing, Molish reaction all are positive, and are Saponin class material.N-butyl alcohol is reclaimed in distilling under reduced pressure, and residue is weighed, and A is 0.17g, and B is that 0.87g, C are that 5.29g, D are 2.60g.Gross weight is 8.93g.
Contain drug regimen composition formula of Tupistra chinensis Bak. extract and preparation method thereof:
Capsule: 1000 amounts (200mg/ grain)
(1) preparation method:
Above-mentioned Tupistra chinensis Bak. extract 200g
(2) method for making:
Raw material is distributed into capsule, every about 300mg.
Claims (11)
1. Tupistra chinensis Bak. extract, be to belong to (Tupistra) plant Tupistra chinensis Bak. (Tupistra chinensis from Liliaceae (Liliaceae) Tupistra chinensis Bak., Baker) Chinese medicine extract that obtains through extraction of rhizome, leaf or herb, it is characterized in that Chinese medicine extract is a steroid oside compound, described extract prepares by following steps: at first Tupistra chinensis Bak. rhizome, leaf or herb are obtained crude extract behind pure reflux or decocting; Then the Tupistra chinensis Bak. crude extract being concentrated the extractum that obtains is dissolved in the water, extract with 4 or 5 carbon alcohol, extract obtains the Tupistra chinensis Bak. extract after reclaiming solvent, or with behind the macroporous resin chromatographic column on the Tupistra chinensis Bak. crude extract, elder generation's water is eluted to the phenolsulfuric acid method and measures no polysaccharide chromogenic reaction, carry out eluting with ethanol then, obtain the Tupistra chinensis Bak. extract behind the concentrate drying of the male position of collection Saponin chromogenic reaction.
2. according to the described Tupistra chinensis Bak. extract of claim 1, it is characterized in that preparing the used alcohol of Tupistra chinensis Bak. crude extract is ethanol or methanol.
3. according to the described Tupistra chinensis Bak. extract of claim 1, it is characterized in that extracting used alcohol is n-butyl alcohol.
4. according to the described Tupistra chinensis Bak. extract of claim 1, it is characterized in that macroporous resin is the HPD-100 macroporous resin.
5. contain following steps according to one of them described Tupistra chinensis Bak. preparation method of extract of claim 1 to 4: water decocts Tupistra chinensis Bak., or obtains the Tupistra chinensis Bak. crude extract with the 1-4 carbon alcoholic solution reflux Tupistra chinensis Bak. of variable concentrations; Then with the separation and purification of Tupistra chinensis Bak. crude extract.
6. according to the described Tupistra chinensis Bak. preparation method of extract of claim 5, it is characterized in that the separation and purification of Tupistra chinensis Bak. crude extract is with behind the HPD-100 macroporous resin chromatographic column on the Tupistra chinensis Bak. crude extract, elder generation's water is eluted to the phenolsulfuric acid method and measures no polysaccharide chromogenic reaction, carry out eluting with ethanol then, obtain the Tupistra chinensis Bak. extract behind the concentrate drying of the male position of collection Saponin chromogenic reaction.
7. according to the described Tupistra chinensis Bak. preparation method of extract of claim 5, it is characterized in that the separation and purification of Tupistra chinensis Bak. crude extract is the Tupistra chinensis Bak. crude extract to be concentrated the extractum that obtains be dissolved in the water, use n-butanol extraction, extract obtains the Tupistra chinensis Bak. extract after reclaiming solvent.
8. pharmaceutical composition contains one of them described Tupistra chinensis Bak. extract of claim 1 to 4 for the treatment of effective dose and acceptable adjuvant pharmaceutically.
9. according to the application of one of them described Tupistra chinensis Bak. extract of claim 1 to 4 in preparation treatment antitumor, antiinflammatory and anticoagulant medicine.
10. according to the application of one of them described Tupistra chinensis Bak. extract of claim 1 to 4 in preparation treatment antitumor drug.
11. according to the application of the described pharmaceutical composition of claim 8 in preparation treatment antitumor, antiinflammatory and anticoagulant medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2005101008321A CN1775267A (en) | 2005-11-03 | 2005-11-03 | A kind of open arrow extract and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2005101008321A CN1775267A (en) | 2005-11-03 | 2005-11-03 | A kind of open arrow extract and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1775267A true CN1775267A (en) | 2006-05-24 |
Family
ID=36765066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005101008321A Pending CN1775267A (en) | 2005-11-03 | 2005-11-03 | A kind of open arrow extract and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1775267A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520445A (en) * | 2013-10-28 | 2014-01-22 | 武汉大学 | Application of Tupistra chinensis in preparation of antitumor drugs |
| CN103751486A (en) * | 2014-01-13 | 2014-04-30 | 姚娟 | Traditional Chinese medicine composition for treating lung cancer |
| CN105859825A (en) * | 2016-05-06 | 2016-08-17 | 广东药学院 | Spirostanol saponins and application thereof |
| CN105924494A (en) * | 2016-05-06 | 2016-09-07 | 广东药学院 | furostanol saponin compounds and application thereof |
| CN106509281A (en) * | 2016-12-21 | 2017-03-22 | 神农架林区中医医院 | campylandra chinensis sore-throat relieving tea and preparation method thereof |
| CN107361403A (en) * | 2017-08-07 | 2017-11-21 | 武汉纺织大学 | One kind contains Extracts of Tupistra chinensis additive in cigarette and preparation method thereof |
| CN119684479A (en) * | 2024-11-20 | 2025-03-25 | 广东医科大学 | A kind of open arrow polysaccharide TCP-1 and its preparation method, identification method and application |
-
2005
- 2005-11-03 CN CNA2005101008321A patent/CN1775267A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520445A (en) * | 2013-10-28 | 2014-01-22 | 武汉大学 | Application of Tupistra chinensis in preparation of antitumor drugs |
| CN103751486A (en) * | 2014-01-13 | 2014-04-30 | 姚娟 | Traditional Chinese medicine composition for treating lung cancer |
| CN105859825A (en) * | 2016-05-06 | 2016-08-17 | 广东药学院 | Spirostanol saponins and application thereof |
| CN105924494A (en) * | 2016-05-06 | 2016-09-07 | 广东药学院 | furostanol saponin compounds and application thereof |
| CN105924494B (en) * | 2016-05-06 | 2017-12-12 | 广东药科大学 | A kind of furostanol saponin class compound and its application |
| CN106509281A (en) * | 2016-12-21 | 2017-03-22 | 神农架林区中医医院 | campylandra chinensis sore-throat relieving tea and preparation method thereof |
| CN107361403A (en) * | 2017-08-07 | 2017-11-21 | 武汉纺织大学 | One kind contains Extracts of Tupistra chinensis additive in cigarette and preparation method thereof |
| CN107361403B (en) * | 2017-08-07 | 2018-09-18 | 武汉纺织大学 | A kind of cigarette of additive in cigarette and preparation method thereof containing Extracts of Tupistra chinensis |
| CN119684479A (en) * | 2024-11-20 | 2025-03-25 | 广东医科大学 | A kind of open arrow polysaccharide TCP-1 and its preparation method, identification method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103191265A (en) | Traditional chinese medicine extract and preparation method thereof | |
| CN102552644B (en) | Anti-tumor use, preparation method and composition of garlic total polysaccharide | |
| CN101850032B (en) | Traditional Chinese medicine composition with anti-tumor effect and preparation method and application thereof | |
| CN1775267A (en) | A kind of open arrow extract and its preparation method and application | |
| CN1899491A (en) | Method for preparing paris polyphylla total saponin and its use | |
| CN104013636A (en) | Anti-tumor pharmaceutical use of pentacyclic triterpene saponin compounds of szechuan melandium root | |
| CN101824014A (en) | Compounds with anti-tumor activity in chloranthus japonicus as well as effective parts and purpose thereof | |
| CN101250175A (en) | Preparation of myricetin, medicinal preparation and new medical usage | |
| CN103735653A (en) | Traditional Chinese medicine extract with anti-tumor activity as well as preparation method and use thereof | |
| CN104069194B (en) | A kind of Chinese medicine composition with antitumaous effect and its production and use | |
| CN102225089B (en) | Pharmaceutical composition for treating cancers, pharmaceutical preparation as well as applications and production methods thereof | |
| CN102872385B (en) | Compound Chinese medicinal composition for treating advanced gastric cancer and preparation method and application thereof | |
| CN108159160B (en) | A combination drug for the treatment of colorectal cancer | |
| CN104257955A (en) | Anti-hepatoma traditional Chinese medicine mixture containing arisaema amurense and production method of anti-hepatoma traditional Chinese medicine mixture | |
| CN101040891A (en) | Preparation method and application of tripterygium hypoglaucum alkaloids | |
| CN100574768C (en) | A kind of anticancer pharmaceutical composition and its production and use | |
| CN103251706A (en) | Traditional chinese medicine composition | |
| CN101428049B (en) | Upper respiratory tract infection resistant medicament composition, preparation and uses thereof | |
| CN103211898B (en) | Traditional Chinese medicine extractive and preparation method thereof | |
| CN101632829B (en) | Anti-hepatofibrosis traditional Chinese medicament composition, preparation method thereof and medicament preparation | |
| CN1961898B (en) | An antitumor compound pharmaceutical composition with barbed stullcap and preparation process thereof | |
| CN1289104C (en) | Anticancer medicine and its preparation | |
| CN1977885A (en) | Antihepatitis medicinal composition | |
| CN102631396B (en) | Anti-lung cancer alstonia-leaf traditional Chinese herbal composite, method for preparing same and application thereof in preparing anti-lung cancer medicine | |
| CN102070700A (en) | Marsdenia tenacissima saponins H and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |